Ras suppressor protein 1 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored RSU1P3 profile across patient tissues and cancer cell-line models. RSU1P3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RSU1P3 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RSU1P3 RNA expression shows 17,710 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUSC, BRCA, and PDAC as cancer lineages where RSU1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSU1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSU1P3 survival associations across molecular data types. RSU1P3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSU1P3 RNA expression–survival associations across cancer types. High RSU1P3 expression shows unfavorable associations in LUSC, BLCA, STAD, THYM, COAD and CHOL. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RSU1P3 RNA expression.
This table summarizes RSU1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RSU1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSU1P3 shows lower tumor expression in THCA and higher tumor expression in BRCA. The BRCA box plot shows higher RSU1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.126, t-test p = .045).
This table shows molecular features associated with RSU1P3 in patient tissues and cancer cell lines. In patient samples, RSU1P3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
